|
1
|
Stupp R, Mason WP, van den Bent MJ, et al:
Radiotherapy plus concomitant and adjuvant temozolomide for
glioblastoma. N Engl J Med. 352:987–996. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Robe PA, Bentires-Alj M, Bonif M, et al:
In vitro and in vivo activity of the nuclear factor-kappaB
inhibitor sulfasalazine in human glioblastomas. Clin Cancer Res.
10:5595–5603. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Bredel M, Scholtens DM, Yadav AK, et al:
NFKBIA deletion in glioblastomas. N Engl J Med. 364:627–637. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Squatrito M and Holland EC: DNA damage
response and growth factor signaling pathways in gliomagenesis and
therapeutic resistance. Cancer Res. 71:5945–5949. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Becherel OJ, Jakob B, Cherry AL, et al:
CK2 phosphorylation-dependent interaction between aprataxin and
MDC1 in the DNA damage response. Nucleic Acids Res. 38:1489–1503.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Lin YC, Hung MS, Lin CK, et al: CK2
inhibitors enhance the radiosensitivity of human non-small cell
lung cancer cells through inhibition of stat3 activation. Cancer
Biother Radiopharm. 26:381–388. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Brown MS, Diallo OT, Hu M, et al: CK2
modulation of NF-κB, TP53, and the malignant phenotype in head and
neck cancer by anti-CK2 oligonucleotides in vitro or in vivo via
Sub-50-nm nanocapsules. Clin Cancer Res. 16:2295–2307. 2010.
|
|
8
|
Eddy SF, Guo S, Demicco EG, et al:
Inducible IkappaB kinase/IkappaB kinase epsilon expression is
induced by CK2 and promotes aberrant nuclear factor-kappaB
activation in breast cancer cells. Cancer Res. 65:11375–11383.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Yu M, Yeh J and Van Waes C: Protein kinase
casein kinase 2 mediates inhibitor-kappaB kinase and aberrant
nuclear factor-kappaB activation by serum factor(s) in head and
neck squamous carcinoma cells. Cancer Res. 66:6722–6731. 2006.
View Article : Google Scholar
|
|
10
|
Siepmann M, Kumar S, Mayer G and Walter J:
Casein kinase 2 dependent phosphorylation of neprilysin regulates
receptor tyrosine kinase signaling to Akt. PLoS One. 5:E131342010.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Horejsí Z, Takai H, Adelman CA, et al: CK2
phospho-dependent binding of R2TP complex to TEL2 is essential for
mTOR and SMG1 stability. Mol Cell. 39:839–850. 2010.PubMed/NCBI
|
|
12
|
Maccario H, Perera NM, Davidson L, Downes
CP and Leslie NR: PTEN is destabilized by phosphorylation on
Thr366. Biochem J. 405:439–444. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Kang H, Jung JW, Kim MK and Chung JH: CK2
is the regulator of SIRT1 substrate-binding affinity, deacetylase
activity and cellular response to DNA-damage. PLoS One.
4:E66112009. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Takeishi Y, Ohashi E, Ogawa K, Masai H,
Obuse C and Tsurimoto T: Casein kinase 2-dependent phosphorylation
of human Rad9 mediates the interaction between human Rad9-Hus1-Rad1
complex and TopBP1. Genes Cells. 15:761–771. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Olsen BB, Issinger OG and Guerra B:
Regulation of DNA-dependent protein kinase by protein kinase CK2 in
human glioblastoma cells. Oncogene. 29:6016–6026. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Ström CE, Mortusewicz O, Finch D, et al:
CK2 phosphorylation of XRCC1 facilitates dissociation from DNA and
single-strand break formation during base excision repair. DNA
Repair. 10:961–969. 2011.PubMed/NCBI
|
|
17
|
Kaminska B, Ellert-Miklaszewska A, Oberbek
A, et al: Efficacy and mechanism of anti-tumor action of new
potential CK2 inhibitors toward glioblastoma cells. Int J Oncol.
35:1091–1100. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Prudent R, Moucadel V, Nguyen CH, et al:
Antitumor activity of pyridocarbazole and benzopyridoindole
derivatives that inhibit protein kinase CK2. Cancer Res.
70:9865–9874. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Pierre F, Chua PC, O’Brien SE, et al:
Pre-clinical characterization of CX-4945, a potent and selective
small molecule inhibitor of CK2 for the treatment of cancer. Mol
Cell Biochem. 356:37–43. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Battistutta R, Cozza G, Pierre F, et al:
Unprecedented selectivity and structural determinants of a new
class of protein kinase CK2 inhibitors in clinical trials for the
treatment of cancer. Biochemistry. 50:8478–8488. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Schneider CC, Hessenauer A, Montenarh M
and Götz C: p53 is dispensable for the induction of apoptosis after
inhibition of protein kinase CK2. Prostate. 70:126–134.
2010.PubMed/NCBI
|
|
22
|
Shehata M, Schnabl S, Demirtas D, et al:
Reconstitution of PTEN activity by CK2 inhibitors and interference
with the PI3-K/Akt cascade counteract the antiapoptotic effect of
human stromal cells in chronic lymphocytic leukemia. Blood.
116:2513–2521. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Li C, Liu X, Lin X and Chen X:
Structure-activity relationship of 7 flavonoids on recombinant
human protein kinase CK2 holoenzyme. Zhong Nan Da Xue Xue Bao Yi
Xue Ban. 34:20–26. 2009.PubMed/NCBI
|
|
24
|
Sarno S, de Moliner E, Ruzzene M, et al:
Biochemical and three-dimensional-structural study of the specific
inhibition of protein kinase CK2 by
[5-oxo-5,6-dihydroindolo-(1,2-a)quinazolin-7-yl] acetic acid (IQA).
Biochem J. 374:639–646. 2003.PubMed/NCBI
|
|
25
|
Zhao M, Ma J, Zhu HY, et al: Apigenin
inhibits proliferation and induces apoptosis in human multiple
myeloma cells through targeting the trinity of CK2, Cdc37 and
Hsp90. Mol Cancer. 10:1042011. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Zhong Y, Krisanapun C, Lee SH, et al:
Molecular targets of apigenin in colorectal cancer cells:
involvement of p21, NAG-1 and p53. Eur J Cancer. 46:3365–3374.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Slusarz A, Shenouda NS, Sakla MS, et al:
Common botanical compounds inhibit the hedgehog signaling pathway
in prostate cancer. Cancer Res. 70:3382–3390. 2010. View Article : Google Scholar
|
|
28
|
Das A, Banik NL and Ray SK: Flavonoids
activated caspases for apoptosis in human glioblastoma T98G and
U87MG cells but not in human normal astrocytes. Cancer.
116:164–176. 2010.PubMed/NCBI
|
|
29
|
Chakravarti A, Zhai GG, Zhang M, et al:
Survivin enhances radiation resistance in primary human
glioblastoma cells via caspase-independent mechanisms. Oncogene.
23:7494–7506. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Miyamoto S: Nuclear initiated NF-κB
signaling: NEMO and ATM take center stage. Cell Res. 21:116–130.
2010.
|
|
31
|
Keller DM, Zeng X, Wang Y, et al: A DNA
damage-induced p53 serine 392 kinase complex contains CK2, hSpt16,
and SSRP1. Mol Cell. 7:283–292. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Tsuchiya Y, Asano T, Nakayama K, Kato T
Jr, Karin M and Kamata H: Nuclear IKKbeta is an adaptor protein for
IkappaBalpha ubiquitination and degradation in UV-induced NF-kappaB
activation. Mol Cell. 39:570–582. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Cheung WL, Turner FB, Krishnamoorthy T, et
al: Phosphorylation of histone H4 serine 1 during DNA damage
requires casein kinase II in S. cerevisiae. Curr Biol. 15:656–660.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Li J and Stern DF: DNA damage regulates
Chk2 association with chromatin. J Biol Chem. 280:37948–37956.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Agullo G, Gamet-Payrastre L, Manenti S, et
al: Relationship between flavonoid structure and inhibition of
phosphatidylinositol 3-kinase: a comparison with tyrosine kinase
and protein kinase C inhibition. Biochem Pharmacol. 53:1649–1657.
1997. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Koch CA, Agyei R, Galicia S, et al: Xrcc4
physically links DNA end processing by polynucleotide kinase to DNA
ligation by DNA ligase IV. EMBO J. 23:3874–3885. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Quiros S, Roos WP and Kaina B: Rad51 and
BRCA2 - new molecular targets for sensitizing glioma cells to
alkylating anti-cancer drugs. PLoS One. 6:E271832011. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Macrae CJ, McCulloch RD, Ylanko J,
Durocher D and Koch CA: APLF (C2orf13) facilitates nonhomologous
end-joining and undergoes ATM-dependent hyperphosphorylation
following ionizing radiation. DNA Repair. 7:292–302. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Iles N, Rulten S, El-Khamisy SF and
Caldecott KW: APLF (C2orf13) is a novel human protein involved in
the cellular response to chromosomal DNA strand breaks. Mol Cell
Biol. 27:3793–3803. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Zwicker F, Ebert M, Huber PE, Debus J and
Weber KJ: A specific inhibitor of protein kinase CK2 delays
gamma-H2Ax foci removal and reduces clonogenic survival of
irradiated mammalian cells. Radiat Oncol. 6:152011. View Article : Google Scholar
|
|
41
|
Neal JA and Meek K: Choosing the right
path: does DNA-PK help make the decision? Mutat Res. 711:73–86.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Hill R and Lee PW: The DNA-dependent
protein kinase (DNA-PK): more than just a case of making ends meet?
Cell Cycle. 9:3460–3469. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Kinner A, Wu W, Staudt C and Iliakis G:
Gamma-H2AX in recognition and signaling of DNA double-strand breaks
in the context of chromatin. Nucleic Acids Res. 36:5678–5694. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Shen J, Channavajhala P, Seldin DC and
Sonenshein GE: Phosphorylation by the protein kinase CK2 promotes
calpain-mediated degradation of IkappaBalpha. J Immunol.
167:4919–4925. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Viatour P, Merville MP, Bours V and
Chariot A: Phosphorylation of NF-κB and IκB proteins: implications
in cancer and inflammation. Trends Biochem Sci. 30:43–52. 2005.
|
|
46
|
Janssens S and Tschopp J: Signals from
within: the DNA-damage-induced NF-κB response. Cell Death Differ.
13:773–784. 2006.
|
|
47
|
Kato T, Delhase M, Hoffmann A and Karin M:
CK2 is a C-terminal IkappaB kinase responsible for NF-kappaB
activation during the UV response. Mol Cell. 12:829–839. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Li N: ATM is required for Ikappa B kinase
(IKK) activation in response to DNA double strand breaks. J Biol
Chem. 276:8898–8903. 2000. View Article : Google Scholar
|
|
49
|
Veuger SJ, Hunter JE and Durkacz BW:
Ionizing radiation-induced NF-κB activation requires PARP-1
function to confer radioresistance. Oncogene. 28:832–842. 2008.
|
|
50
|
Hunter JE, Willmore E, Irving JAE,
Hostomsky Z, Veuger SJ and Durkacz BW: NF-κB mediates
radio-sensitization by the PARP-1 inhibitor, AG-014699. Oncogene.
31:251–264. 2012.
|
|
51
|
Tsuboi Y, Kurimoto M, Nagai S, et al:
Induction of autophagic cell death and radiosensitization by the
pharmacological inhibition of nuclear factor-kappa B activation in
human glioma cell lines. J Neurosurg. 110:594–604. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Berger R, Jennewein C, Marschall V, et al:
NF-κB is required for Smac mimetic-mediated sensitization of
glioblastoma cells for γ-irradiation-induced apoptosis. Mol Cancer
Ther. 10:1867–1875. 2011.
|
|
53
|
Asai A, Miyagi Y, Sugiyama A, et al:
Negative effects of wild-type p53 and s-Myc on cellular growth and
tumorigenicity of glioma cells. Implication of the tumor suppressor
genes for gene therapy. J Neurooncol. 19:259–268. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Wischhusen J, Naumann U, Ohgaki H,
Rastinejad F and Weller M: CP-31398, a novel p53-stabilizing agent,
induces p53-dependent and p53-independent glioma cell death.
Oncogene. 22:8233–8245. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Meek DW and Cox M: Induction and
activation of the p53 pathway: a role for the protein kinase CK2?
Mol Cell Biochem. 356:133–138. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Cancer Genome Atlas Research Network:
Comprehensive genomic characterization defines human glioblastoma
genes and core pathways. Nature. 455:1061–1068. 2008. View Article : Google Scholar : PubMed/NCBI
|
